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Osteopontin (OPN), a senescence-associated secretory phenotype factor, is in-
creased	in	patients	with	nonalcoholic	fatty	liver	disease	(NAFLD).	Cellular	senescence	
has been associated with age-dependent hepatosteatosis. Thus, we investigated the 
role of OPN in the age-related hepatosteatosis. For this, human serum samples, an-
imal models of aging, and cell lines in which senescence was induced were used. 
Metabolic	fluxes,	lipid,	and	protein	concentration	were	determined.	Among	individu-
als with a normal liver, we observed a positive correlation between serum OPN levels 
and increasing age. This correlation with age, however, was absent in patients with 
NAFLD.	In	wild‐type	(WT)	mice,	serum	and	liver	OPN	were	increased	at	10	months	
old (m) along with liver p53 levels and remained elevated at 20m. Markers of liver 
senescence increased in association with synthesis and concentration of triglycerides 
(TG)	 in	10m	OPN‐deficient	 (KO)	hepatocytes	when	compared	to	WT	hepatocytes.	
These changes in senescence and lipid metabolism in 10m OPN-KO mice liver were 
associated with the decrease of 78 kDa glucose-regulated protein (GRP78), induction 
of	ER	stress,	and	the	increase	in	fatty	acid	synthase	and	CD36	levels.	OPN	deficiency	





Hepatosteatosis is the earliest stage, and it is caused by the accumu-
lation	of	fat	in	the	hepatocytes.	Increased	fatty	acid	(FA)	uptake	from	
the diet and/or peripheral tissues, increased lipogenesis, defects in 
lipid oxidation, and/or export to circulation in VLDL particles induce 
their aberrant accumulation that can lead, in some patients, to pro-
gression	to	nonalcoholic	steatohepatitis	 (NASH),	 fibrosis,	cirrhosis,	
and/or hepatocellular carcinoma (HCC) (Friedman et al., 2018).
Epidemiological	 studies	 have	 demonstrated	 that	 NAFLD	 and	
NASH	are	common	among	the	elderly	(Bertolotti	et	al.,	2014).	In	old	
age, fat is redistributed outside the usual fat deposits and lipids can 
accumulate in nonadipose tissues like skeletal muscle, heart, and 
liver. Thus, aging is associated with an increase in the lipid accumu-
lation within the liver that may compromise the normal function due 
to	lipotoxicity	(Slawik	&	Vidal‐Puig,	2006).
Osteopontin (OPN) is a multifunctional protein that is expressed 
in a variety of tissues and has many functions, both physiological 
and	pathological	(Ashkar	et	al.,	2000;	Ramaiah	&	Rittling,	2007).	It	is	
involved in liver pathologies and acts as a modulator of liver lipid me-
tabolism (Nunez-Garcia et al., 2017; Nuñez-Garcia et al., 2018). OPN 
is	involved	in	NAFLD	pathogenesis	(Kiefer	et	al.,	2011),	and	its	liver	
expression is increased in obesity and correlates with steatosis and 
insulin	resistance	(Gómez‐Ambrosi	et	al.,	2007).	OPN	expression	is	
also upregulated in liver cancers such as in HCC and cholangiocarci-
noma	(Wen,	Jeong,	Xia,	&	Kong,	2016;	Zheng	et	al.,	2018).	Regarding	
its	role	as	a	metabolic	modulator,	it	controls	the	fate	of	acetyl‐CoA	
in liver (Nunez-Garcia et al., 2017; Nuñez-Garcia et al., 2018) and re-
wires liver lipid metabolism after partial hepatectomy (Nuñez-Garcia 
et al., 2018). OPN is considered a senescence-associated secretory 
phenotype	(SASP)	factor	(Flanagan	et	al.,	2017;	Pazolli	et	al.,	2009).	
SASP	factors	are	mainly	cytokines,	chemokines,	and	proteases	with	
autocrine and paracrine effects that affect the neighboring cells 
and	 are	 able	 to	 induce	 senescence	 (Coppé,	 Desprez,	 Krtolica,	 &	
Campisi,	 2010;	Malaquin,	Martinez,	&	Rodier,	2016).	The	accumu-
lation of senescent cells can lead to inflammation and in turn lead 
to	further	senescence	of	surrounding	cells.	SASP	may	be	beneficial	
because it can help maintain homeostasis by clearing senescent cells 
and, thereby, reduce the tissue damage; however, if senescent cells 
are not cleared and accumulated, detrimental effects appear con-
tributing to inflammation and to making surrounding cells senescent 
(Lau	&	David,	2019;	Malaquin	et	al.,	2016).
Senescence is a stable cell cycle arrest mediated through ac-
tivation	 of	 p53/p21	 and/or	 Rb/p16	 pathways	 (Munoz‐Espin	 &	
Serrano,	 2014).	 Senescent	 cells	 have	 been	 found	 in	 the	 livers	 of	
NAFLD	and	cirrhotic	patients	and	of	high‐fat	diet	fed	and	genetically	
obese	mice	(Aravinthan	&	Alexander,	2016;	Ogrodnik	et	al.,	2017).	
Cellular senescence also drives age-dependent hepatosteatosis 
(Ogrodnik et al., 2017). However, the mechanisms involved in senes-
cence‐induced	NAFLD	progression	remain	poorly	understood.	 It	 is	
recognized that the aging liver is potentially at risk of injury because 
of its inability to respond to stresses. In the aging liver, a significant 
proportion	of	hepatocytes	develop	a	 senescent	phenotype	 (Wang	
et al., 2009), and the aging liver exhibits decreased capacity for 
liver	regeneration	(Schmucker	&	Sanchez,	2011)	and	is	 less	able	to	




Here, we investigated the role of OPN in the aging-related 
metabolic	fatty	liver	disease.	We	used	serum	samples	from	obese	
and nonobese patients, animal models of aging, and cell lines and 
found that OPN is necessary to prevent age-related liver dis-
ease. The results showed that the loss of OPN leads to earlier 
cellular senescence, ER stress, increased de novo lipogenesis, and 
increased lipid uptake, altogether promoting fatty liver disease. 
This study also demonstrated that expression of liver OPN is reg-
ulated, at least in part, by p53 in cellular models of senescence 
and	NAFLD.
2  | RESULTS
2.1 | Aging increases osteopontin in liver and serum
As	OPN	is	secreted	into	the	bloodstream,	we	first	assessed	if	OPN	
is associated with aging by measuring serum OPN levels in a cohort 
in senescent cells also diminished GRP78, the accumulation of intracellular TG, and 
the	 increase	 in	CD36	 levels.	 In	20m	mice,	OPN	 loss	 led	 to	 increased	 liver	 fibrosis.	
Finally, we showed that OPN expression in vitro and in vivo was regulated by p53. 
In conclusion, OPN deficiency leads to earlier cellular senescence, ER stress, and TG 
accumulation during aging. The p53-OPN axis is required to inhibit the onset of age-
related hepatosteatosis.
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of individuals of varying ages and who were found to have a normal 
liver (NL) (n	=	34)	(Figure	1a)	(Table	1).	The	results	showed	a	positive	
correlation between serum OPN concentration and age (Figure 1a). 
Given that OPN is increased in liver (Lima-Cabello et al., 2010) and 
serum	of	NAFLD	patients	 (Nunez‐Garcia	 et	 al.,	 2017),	OPN	 levels	
were	also	measured	in	a	cohort	of	NAFLD	patients	(n = 89) (Figure 1b) 
(Table 1). The correlation between serum OPN concentration and 
age	was	lost	in	NAFLD	patients,	in	which	OPN	levels	were	already	
high in younger patients (Figure 1b).
To investigate the involvement of OPN in age-related develop-
ment of fatty liver, animal models that recapitulate aging were gen-
erated. In this model, 3-month-old (3m) mice represent young mice, 
10-month-old (10m) mice intermediate-age mice, and 20-month-
old mice (20m) aged mice. The results showed that serum OPN 
F I G U R E  1   Osteopontin serum and liver levels increase during aging. (a) Serum samples from normal liver (NL) individuals (n	=	34),	
(b)	nonalcoholic	fatty	liver	disease	(NAFLD)	patients	(n	=	89),	and	nonobese	NAFLD	patients	(n	=	13)	were	quantified	by	ELISA	to	asses	
circulating	OPN	levels.	(c)	Serum	OPN	from	3‐,	10‐,	and	20‐month‐old	(m)	wild‐type	(WT)	mice	was	quantified	by	ELISA	and	liver	OPN	levels	
were assessed by immunoblotting using transferrin as loading control (n	=	4–8).	Correlation	analysis	was	tested	using	the	Pearson	correlation	
test. Values are means ± SEM. Significant differences are denoted by *p < 0.05, **p < 0.01, and ***p < 0.001 (Student's t test)
(c)
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concentration increased from 3 to 10m, and the increase maintained 
in 20m mice (Figure 1c). Total Liver OPN levels were also analyzed, 
and a similar profile was obtained. OPN protein levels were in-
creased in 10m mice as compared to 3m mice, and these levels were 
maintained at 20m (Figure 1c).
2.2 | OPN deficiency in mice results in an early 
increase in liver lipid storage during aging






Liver lipid analysis showed a premature increase in lipid concen-
tration	in	10m	OPN‐KO	mice	compared	to	their	age‐matched	WTs	
(Figure 2a). In fact, there was a rise in triglycerides (TG), cholesteryl 
ester	 (CE),	 fatty	acids	 (FA),	 and	diglycerides	 (DG)	 concentration	at	
10m that maintained at 20m. Thus, during aging, fluctuations in liver 
lipid	concentration	differ	between	WT	and	OPN‐KO	mice	(Figure	2a);	
in	WT	mice,	the	peak	of	concentration	for	all	lipids	was	observed	at	
20m, being lipid storage similar at 3 and 10m (Figure 2a,b); OPN-KO 
mice on the other hand accumulated liver lipids at an earlier age. Even 
more, the results showed that serum TG was increased in 10m and 
20m	OPN‐KO	mice	when	compared	to	their	WT	controls	(Figure	2c).	
Serum	FAs	also	increased	in	10m	OPN‐KO	animals.	However,	serum	
total cholesterol (Chol) did not change when comparing age or gen-
otype (Figure 2c).
Others have previously reported that young OPN-KO mice are 
protected from diet-induced hepatosteatosis (Kiefer et al., 2011; 
Lancha	 et	 al.,	 2014).	 However,	 given	 the	 observed	 early	 accumu-
lation of lipid in the OPN-KO mice liver during aging, lipid storage 
and hepatosteatosis were also measured in the HFD-fed 20m mice. 
The lipid concentration (Figure 2a) and accumulation of lipid drop-
lets (Figure 2b) showed that aged OPN-KO mice were no longer 
protected from diet-induced hepatosteatosis. The results showed 
that at 20m, the de novo	 lipogenesis	was	 decreased	 (Figure	 S1A);	
however, increased esterification of fatty acids into more complex 
lipids (Figure S1B) associated with increased levels of the fatty acid 
transporter	CD36	were	observed	 (Figure	S1C).	Besides,	 serum	TG	
levels	were	increased	(Figure	2c).	Although	the	final	body	weight	of	
HFD-fed 20m OPN-KO mice was similar to their age-matched HFD-
fed	WT	mice	 (Figure	S1D),	 they	developed	a	greater	degree	of	 in-
sulin resistance as demonstrated by the insulin tolerance test (ITT) 
(Figure	S1E),	insulin	levels,	and	HOMA‐IR	(Figure	S1F).
2.3 | OPN deficiency induces senescence-
associated hepatosteatosis
Increased lipid storage in liver is due to a misbalance between pro-
cesses that control lipid input and output. To ascertain the mecha-
nisms involved in the increased lipid storage, de novo lipogenesis and 
the	 esterification	of	 fatty	 acids	were	measured.	We	used	hepato-
cytes	from	10m	WT	and	OPN‐KO	mice	because	10m	OPN‐KO	mice	
exhibited upregulation in liver and serum lipids. The results showed 
that de novo synthesis of TG, DG, and CE and the esterification of 
oleate into TGs were increased in OPN-KO mice (Figure 3a), but 
no changes were observed in the incorporation of oleate into DG 
or	CE	(Figure	3a).	Protein	levels	of	fatty	acid	synthase	(FAS)	which	
is	 involved	 in	 fatty	 acid	 synthesis,	 and	CD36	which	 is	 involved	 in	
fatty acid uptake (Figure 3b), were also augmented, but no signifi-
cant	changes	were	observed	in	the	pACC	and	ACC	levels	(Figure	3b).	
Catabolism of fatty acids through beta oxidation (β-oxidation) (a 
mechanism involved in lipid output) was also assessed by the pro-
duction	of	acid	soluble	metabolites	(ASM)	and	CO2.	We	did	not	de-
tect any statistically significant difference in palmitate β-oxidation 
between	both	groups	of	mice	(Figure	S2A).
Loss of proteostasis is a hallmark of aging (López-Otín, Blasco, 
Partridge,	 Serrano,	 &	 Kroemer,	 2013).	 The	 endoplasmic	 reticulum	
(ER) is an important organelle for regulating lipid homeostasis and 
protein	 synthesis	 (Han	 &	 Kaufman,	 2016).	 Many	 insults	 can	 dis-
turb ER homeostasis, which lead to ER stress and activation of the 
TA B L E  1   Demographic, metabolic, biochemical, and histological 









BMI (kg/m2) 28.1 39.42*** 25.96***
Age(Years) 48.3 50.5 52.92
Male gender % 32.4 31.7 46
Female gender % 67.6 68.3 54
TG (mg/dl) 104.3 144.51*** 128.1*
Glucose (mg/dl) 95.4 93.7 104
CHOL (mg/dl) 188.4 169.41* 201.15***
CHOL-HDL (mg/dl) 49.9 38.86*** 53.15***
ALT	(IU/L) 19.2 40.68*** 34.620
AST	(IU/L) 18.1 29.55*** 25.690
Insulin (mU/ml) 6.6 11.76*** 6.9
Steatosis %
Grade 0 100 0 0
Grade 1 58.0 84.6
Grade 2 27.0 15.4
Grade 3 15.0 0
Note: Data are the mean or percentage (%). Values are means of n	=	34	
for NL, n	=	89	for	NAFLD	and	n	=	13	for	nonobese	NAFLD	patients.	




aminotransferase; BMI, body mass index; CHOL, cholesterol; HDL, 
high-density lipoprotein; TG, triglyceride.
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unfolded protein response (UPR). The UPR might lead to increased 
lipogenesis, thus contributing to lipotoxicity. On the other hand, 
lipid accumulation per se can also perturb ER function, which then 
generates	ER	stress	 (Basseri	&	Austin,	2012).	ER	stress,	 therefore,	
can activate pathways involved in accumulation of lipids in hepato-
cytes, which in turn exacerbates ER stress-mediated increase in 




HFD. Values are means ± SEM. Significant differences when comparing genotypes of the same age-group are denoted by *p < 0.05, **p < 0.01, 
and ***p < 0.001 and #p < 0.05, ##p < 0.01, and ###p < 0.001 when comparing with previous age-group in the same genotype (Student's t test)
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F I G U R E  3   Increased lipid synthesis is linked to markers of senescence and ER stress in 10-month-old OPN-KO mice liver. (a) Hepatocytes 
isolated	from	10‐month‐old	(m)	WT	and	OPN‐KO	mice	were	cultured	in	medium	with	[3H]acetate	or	[3H]oleate	for	4	hr.	Lipids	were	
extracted and radioactivity incorporated into TG, DG, and CE was assessed by liquid scintillation (n	=	5).	(b)	Fatty	acid	synthase	(FAS),	
phosphorylated,	and	total	acetyl‐CoA	carboxylase	(ACC)	and	CD36	protein	levels	of	10	m	WT	and	OPN‐KO	mice	were	assessed	by	
immunoblotting using transferrin as loading control (n	=	5–8).	(c)	Immunoblot	analysis	of	10	m	mice	of	GRP78,	total	and	phosphorylated	
eIF2α and IRe1a protein from liver extract was assessed using transferrin as loading control (n	=	5–6).	(d)	Liver	senescence‐associated	(SA)	
β‐galactosidase‐positive	area	percentage	was	quantified	in	10	m	WT	and	OPN‐KO	mice.	Immunoblot	analysis	of	p21	protein	from	liver	
extract was assessed using transferrin as loading control (n = 5). Significant differences when comparing genotypes of the same age-group 
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lipid storage and induce a vicious positive-feedback cycle, and per-
sistence of ER stress may lead to development and/or progression of 
liver disease (Lebeaupin et al., 2018).
The decrease in the amount of chaperone proteins is a hallmark 
of	aging	(Erickson	et	al.,	2006)	and	may	be	an	activator	of	ER	stress	
(Klaips,	Jayaraj,	&	Hartl,	2018).	Thus,	we	next	investigated	whether	
F I G U R E  4   OPN deficient cells are more vulnerable to senescence. (a) HepG2 cells were treated with hydrogen peroxide (H2O2), 
Palbociclib	(Palbo)	(2	µM),	or	vehicle	(Veh).	Senescence	induction	was	assessed	with	the	senescence‐associated	(SA)‐β-galactosidase 
staining. OPN protein levels from HepG2 cells were measured by immunoblotting using glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH)	as	loading	control.	Secreted	OPN	in	the	media	was	measured	by	ELISA	(n	=	4–7).	(b)	OPN‐deficient	cells	(siOPN),	their	controls	
(siCtrl), control (Ctrl), and recombinant OPN (rOPN) treated HepG2 cells were incubated either with Palbo (2 µM) to induce senescence or 
with	Veh.	SA‐β-galactosidase staining was performed, and the percentage of positive cells was evaluated (n	=	4–6).	(c)	rOPN‐treated	cells	
(rOPN) and their control cells (Ctrol) were treated with Palbo (2 µM), to induce senescence, or vehicle (Veh). Phosphorylated Rb protein 
(ppRB)	levels	were	measured	by	immunoblotting	to	study	palbociclib	effect	using	GAPDH	as	loading	control	(n = 3). Values are means ± SEM. 
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the early lipid accumulation in OPN-KO mice during aging could be 
associated with altered levels of chaperones. Interestingly, the re-
sults showed that in 10m OPN-KO mice livers, levels of the chap-
erone GRP78 were decreased while levels of phosphorylated eIF2α 
(peIF2α) and the peIF2α/eIF2α ratio were increased (Figure 3c). No 
changes were observed in the IRE1α branch of UPR (Figure 3c). 
Altered	mTOR	signaling	could	be	linked	to	the	activation	of	ER	stress	
(Liu	&	Sabatini,	2020),	 the	results	showed	that	phosphorylation	of	
mTOR was decreased in OPN-KO mice (Figure S2B), while there was 
a	tendency	toward	decrease	in	that	of	S6	(Figure	S2B).
It is also well recognized that proteostasis prevents cellular senes-
cence (Kim et al., 2018), and senescent cells can contribute to age-re-
lated tissue degeneration and fat accumulation (Ogrodnik et al., 2017). 
Therefore, we also analyzed markers of senescence in 10m mice liv-
ers. In 10m OPN-KO mice livers, the increased β‐galactosidase	(SA‐
β-galactosidase) and p21 levels (Figure 3d) showed the induction of 
a senescence phenotype in liver when compared to the age-matched 
WT	mice.	Levels	of	γH2AX,	indicating	DNA	damage,	were	also	mea-
sured; however, they were undetectable (data not shown).
Considering that deficient autophagy in the liver impairs the mo-
bilization	of	TGs	into	FAs,	resulting	in	steatosis	 (Singh	et	al.,	2009)	
and that it could have a direct effect on triggering senescence and 
quiescence (Rajendran et al., 2019), we analyzed levels of proteins in-
volved	in	autophagy.	We	found	no	statistically	significant	differences	
in	ATG5,	ATG7,	or	LC3	levels	in	10m	OPN‐KO	mice	(Figure	S2C).
To establish a causality of events, and to validate these results in 
an in vitro model of senescence, palbociclib (Palbo) (a cyclin-depen-
dent	protein	kinase	4/6	inhibitor)	or	hydrogen	peroxide	(H2O2) were 
used	to	induce	senescence	in	HepG2	cells.	As	OPN	is	a	SASP	factor	
and senescence is a hallmark of aging, intracellular and secreted OPN 
levels were measured in HepG2 cells after the induction of senes-
cence.	 Induction	of	senescence,	as	the	SA‐β-galactosidase staining 
showed	(Figure	4a),	increased	intracellular	and	secreted	OPN	protein	
levels	 (Figure	4a).	When	OPN	knocked‐down	(siOPN)	 (Figure	S3A)	
cells where treated with vehicle no differences were observed in 
SA‐β-galactosidase-positive cells as compared to their controls 
(Figure	 4b).	 However,	 when	 cells	 were	 treated	with	 palbo,	 siOPN	
cells	showed	higher	percentage	of	SA‐β-galactosidase-positive cells 
F I G U R E  5   Lack of OPN in senescent cells induces the decrease of GRP78 and the storage of triglycerides. OPN-deficient cells (siOPN) 
and their controls (siCtrl) were treated with Palbociclib (Palbo) to induce senescence. (a) GRP78, total and phosphorylated eIF2α, p21, and 
γH2AX	protein	levels	were	measured	by	immunoblotting	using	glyceraldehyde‐3‐phosphate	dehydrogenase	(GAPDH)	as	loading	control	
(n	=	4–8).	(b)	Intracellular	TG	levels	were	measured	(C)	FAS,	total	and	phosphorylated	acetyl‐CoA	carboxylase	(ACC),	and	CD36	protein	
levels	were	measured	using	GAPDH	as	a	loading	control	(n	=	4).	Values	are	means	±	SEM. Significant differences are denoted by *p < 0.05, 
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of OPN as a factor that prevents senescence.
OPN knockdown (i.e., siOPN) during palbo-associated senes-
cence also led to decreased GRP78 but increased γH2AX	and	p21	
level expression (Figure 5a). By contrast, GRP78 levels remained 
unaltered and γH2AX	 decreased,	 while	 p21	 levels	 increased	
(Figure S3B) when OPN knockdown occurred under normal (i.e., non 
senescence) conditions. In sum, these results indicate that 1-the in-
duction of senescent cells in vitro promotes the generation and se-
cretion of OPN; and 2-the induction of senescence in vitro is more 
marked when OPN is absent.
Changes in levels of GRP78 and markers of senescence during 
palbo treatment were also associated with an increase in HepG2 TG 
concentration	(Figure	5b)	and	the	upregulation	of	CD36	(Figure	5c).	
No changes, however, were observed in levels of the pro-lipogenic 
proteins,	 FAS	 or	 ACC	 (Figure	 5c	 and	 Figure	 S3D).	 It	was	 recently	
reported	that	CD36	 is	 rapidly	upregulated	 in	multiple	cell	 types	 in	
response to senescent stimuli (Chong et al., 2018). By comparison, 
TG	and	CD36	levels	maintained	unchanged	when	HepG2	cells	were	
not treated with the senescence inducer (Figure S3C,D). Thus, OPN 
deficiency increases cellular vulnerability to senescence and the se-
nescent-associated altered processes. These in vitro experiments 
recapitulate results obtained in vivo, and imply that reduced OPN 
levels in the setting of cellular senescence will increase lipid storage 
in vivo, will enhance activation of ER stress and de novo lipogenesis.
2.4 | OPN deficiency promotes age-related fibrosis
Human	NASH	and	fibrosis	are	related	to	increased	OPN	levels	(Glass	
et al., 2018), and the current results show that liver OPN prevents 
age-related early accumulation of lipids, senescence, and ER stress. 
We	next	evaluated	whether	OPN	was	also	 required	 to	prevent	 fi-
brosis in the aged mice. The results showed that at 3m and 10m, 
fibrosis	 in	 OPN‐KO	 mice	 was	 comparable	 with	 age‐matched	WT	
mice	 (Figure	 S4A).	 Similar	 results	were	noted	 for	 F4/80,	 a	marker	
of	macrophages/	kupffer	cells	(Figure	S4A),	and	SA‐β-galactosidase 
(Figure S2D). 20m OPN-KO mice however developed significantly 
more	 liver	 fibrosis	 (Figure	6a)	and	had	higher	 levels	of	F4/80	pro-
tein	(Figure	6b)	compared	with	WT	mice	under	HFD	conditions.	AST	
levels were also significantly higher in 20m HFD-fed OPN-KO mice 
(Figure	6c).	Fibrosis	was	also	upregulated	in	the	CD‐fed	20m	OPN‐KO	
mice	while	F4/80	immunostaining	remained	unaltered	(Figure	6a,b).	
Even	 though	 fibrosis	 and	 F4/80	 increased	 in	 the	 HFD‐fed	 20m	
OPN‐KO	mice,	 lipid	 storage	maintained	 unaltered	 (Figure	 2a).	We	
next analyzed induction of ER stress and senescence. The results 
showed that while GRP78, activation of the PERK branch of UPR 





2.5 | Liver OPN is p53 regulated
p53 signaling mediates cellular senescence, and it is involved in 
aging	 (Munoz‐Espin	 &	 Serrano,	 2014;	 Rufini,	 Tucci,	 Celardo,	 &	
Melino, 2013). p53 and other p53 family members also regulate 
metabolic	 pathways	 (Napoli	 &	 Flores,	 2017;	 Porteiro,	 Fondevila,	
Delgado, et al., 2017) and the development of hepatosteatosis 
(Porteiro, Fondevila, Buque, et al., 2017). OPN has been described 
as	 a	 p53	 target	 in	 fibroblasts	 (Morimoto,	 Sasaki,	 Ishida,	 Imai,	 &	
Tokino,	2002).	As	both	OPN	and	p53	play	a	role	in	senescence,	lipid	
metabolism and hepatosteatosis, we analyzed if OPN could also be 
a target of p53 in liver. Interestingly, the data showed that liver p53 
levels increased during aging, mirroring a similar pattern to OPN in 
the animal model of aging (Figure 7a), and that loss of p53 resulted 
in a dramatic decrease in OPN in both CD- and HFD-fed mice; the 
decrease was particularly marked among HFD-fed mice (Figure 7b). 
These data are consistent with prior reports, which showed that liver 
OPN increased with HFD (Bertola et al., 2009). Over-expression 
of p53 in vivo, as others performed before (Porteiro, Fondevila, 
Delgado, et al., 2017), also increased liver OPN levels (Figure 7c), 
even	in	p53‐KO	mice	(Figure	S5A).
Data obtained from the Cell Line Encyclopedia (© 2019 The 
Broad	Institute	of	MIT	&	Harvard)	showed	that	the	cell	line	with	the	
least p53 expression, the Hep3B, also had the lowest OPN expres-
sion. In vitro experiments showed that the decreased p53 levels in 
HepG2	cells	using	a	siRNA	led	to	diminish	intracellular	and	secreted	
OPN levels (Figure 7d). Earlier, we showed that induction of senes-
cence	with	Palbo	increased	OPN	levels	(Figure	4a).	Here,	we	found	
that cells deficient in p53 (i.e., either p53-silenced cells or p53-null 
cells) were unable to upregulate OPN expression even after treat-
ment with Palbo (Figure 7e; Figure S5B) or H2O2 (Figure S5C), con-
firming that p53 is a master regulator of hepatocyte OPN expression.
3  | DISCUSSION
Aging	 is	 a	 complex	 multifunctional	 process,	 in	 which	 metabolism	
plays an important role (López-Otín et al., 2013). Indeed, many aging-
related diseases have a metabolic component. Epidemiological stud-
ies	have	demonstrated	that	NAFLD	and	NASH	are	common	among	
the	elderly	(Bertolotti	et	al.,	2014)	although	some	pieces	of	evidence	
suggest	 that	 very	 old	 age‐groups	 show	 a	 decrease	 in	NAFLD	 and	
HCC	 prevalence	 (Sheedfar,	 Biase,	 Koonen,	 &	 Vinciguerra,	 2013).	
Senescence is one of the hallmarks of aging and is a permanent 
state of cell cycle arrest in response to different stresses, thus, a 
cellular defense mechanism (López-Otín et al., 2013). This pro-
cess takes place in several tissues during different physiological 
and pathological conditions. Senescence of hepatocytes is a fea-
ture of chronic liver disease independent of etiology and plays an 
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important	role	in	the	progression	of	chronic	liver	disease	(Aravinthan	
&	Alexander,	2016).	Cellular	 senescence	has	been	associated	with	
age-dependent hepatosteatosis, and it correlates with severity of 
NAFLD	 (Ogrodnik	 et	 al.,	 2017).	 Specifically,	 the	 accumulation	 of	
senescent hepatocytes has been shown to promote progression 
(Aravinthan	 &	 Alexander,	 2016).	 Previous	work	 has	 described	 os-
teopontin (OPN) as a senescence-associated secretory phenotype 
(SASP)	 factor	 (Flanagan	et	al.,	2017;	Pazolli	et	al.,	2009).	Although	
senescence-associated cell cycle exit likely evolved as an antitumor 
mechanism,	SASP	contains	both	anti‐	and	pro‐tumorigenic	potential	
(Lau	&	David,	2019).	Thus,	identification	and	characterization	of	the	
SASP	 factors	 that	are	pro‐	and	 those	 that	are	antitumorigenic	de-
pending on the contexts and tissue is crucial. Here, we investigated 
the role of OPN in the age-related hepatosteatosis. Data showed a 
positive correlation between serum OPN levels and increasing age 
in	humans.	Correlation	however,	lost	in	NAFLD	patients	where	OPN	
levels are already higher in younger patients. Similar results were ob-
tained in mice, where liver and serum OPN increases with age, mir-
roring the same pattern as p53, a regulator of cellular senescence, 
and whose downregulation has been linked to hepatosteatosis and 
induction of ER stress (Porteiro, Fondevila, Delgado, et al., 2017). 
Finally, we also found that when senescence was induced in HepG2 
cells, OPN levels were also increased in cells and culture medium.
Thus, to determine whether the age-related increase in OPN was 
protective or deleterious for hepatosteatosis and liver disease pro-
gression; lipid storage, metabolic fluxes, ER stress, and senescence 
were	 also	 studied	 in	OPN‐KO	mice	 during	 aging.	 Young	OPN‐KO	
mice are protected from diet-induced hepatosteatosis (Kiefer 
et	 al.,	 2011;	 Lancha	 et	 al.,	 2014).	 Older	 mice,	 which	 lacked	 OPN	
however, accumulated liver lipids, developed liver steatosis, and had 
higher serum TG levels in association with insulin resistance at an 
earlier	age	than	the	WT	mice.
We	previously	observed	that	in	young	mice,	OPN	is	a	regulator	of	
liver lipid metabolism during regeneration after partial hepatectomy 
(Nuñez‐Garcia	 et	 al.,	 2018).	 As	 intermediate‐age	 (10m)	 OPN‐KO	
mice was noted to store more lipids, we investigated the mecha-
nisms	by	which	OPN	regulate	liver	lipid	metabolism.	We	found	that	
increased lipid synthesis and uptake were linked to higher levels 
of	 fatty	 acid	 synthase	 (FAS)	 and	CD36.	We	also	 found	 that	mark-
ers of senescence and activation of the unfolded protein response 
PERK branch (linked to decreased GRP78 chaperone levels) were in-
creased. Loss of proteostasis and senescence are hallmarks of aging 
(López-Otín et al., 2013), and several studies have demonstrated 
that the decrease in chaperone number is associated with aging 
(Lee et al., 2017) and can be a cause of the increased ER stress with 
aging. Other studies have also shown that forced over-expression 
of GRP78 attenuates steatosis by inhibiting sterol regulatory ele-
ment-binding protein (SREBP-1c) (Kammoun et al., 2009). Thus, the 
decrease	in	GRP78	levels	may	activate	SREBP‐1c	(given	that	FAS	is	
increased and is one of its downstream targets) and induce de novo 
lipid synthesis.
OPN	has	been	linked	to	fibrosis	and	NASH	in	humans	and	animal	
models. In fact, OPN has been described as a profibrogenic factor 
and its deficiency avoids fibrosis (Coombes et al., 2015). The role 
of OPN however is quite different during aging. Liver fibrosis was 
increased in 20m (aged) OPN-KO mice, and this was enhanced after 
a HFD. Induction of fibrosis by senescent hepatocytes is generally a 
way of limiting tissue injury as part of wound healing process. The 
accumulation of senescent hepatocytes leads to continued acti-
vation of hepatic stellate cells, which in turn, leads to liver fibrosis 
(Aravinthan	&	Alexander,	 2016).	 Liver	 fibrosis	 (observed	mainly	 in	
HFD‐fed	 OPN‐KO	 mice)	 was	 associated	 with	 inflammation,	 DNA	
damage, and insulin resistance. In combination, these factors con-
tribute to the development of liver fibrosis. It is unclear however 
whether the inflammation and fibrosis observed in the aging mice 
are consequences of a premature liver lipid storage or are de-
pendent on other dysregulated mechanisms that activate during 
aging. Supporting the protective role of OPN, other studies have 
also shown a protective role of OPN in alcoholic hepatitis (Lazaro 
et al., 2015; Magdaleno et al., 2018).
Finally, previous work has shown that OPN is a p53 target in fi-
broblasts	(Morimoto	et	al.,	2002).	p53	represses	some	of	the	SASP	




profile can greatly variate depending on the cell type and effector. 
Concerning liver disease, it has been demonstrated that p53 regu-
lates	SASP	of	hepatic	stellate	cells	(Lujambio	et	al.,	2013).	SASP	also	
regulates genes affecting macrophage function. In fact, p53 signal-
ing,	 through	 SASP,	 influences	 macrophage	 polarization	 (Lujambio	
et al., 2013). Precisely, induction of senescence by p53 activation in 
malignant hepatocytes showed a reduction in the tumor size caused 
by	 SASP‐mediated	 recruitment	 of	 immune	 cells	 to	 the	 tumors	
(Lujambio et al., 2013). Here, the results showed in vivo and in vitro 
that normal expression of p53 is required to ensure the homeostasis 
of OPN in liver and in HepG2 cells. Thus, p53-OPN axis is required 
for maintaining the liver health during aging.
In summary, OPN deficiency increases the susceptibility of the 
liver	 to	aging	and	aging‐associated	 liver	disease.	As	OPN‐deficient	
mice become older, increased levels of senescence, ER stress, hep-
atosteatosis,	DNA	damage,	 fibrosis,	 and	 inflammation	 appear.	 The	
F I G U R E  6   Liver fibrosis is increased in aged high-fat diet fed OPN-KO mice. (a) Sirius Red and Masson trichrome stainings were 
performed	and	evaluated	to	assess	tissue	fibrosis	in	20‐month‐old	(m)	WT	and	OPN‐KO	mice	fed	a	chow	(CD)	and	a	high‐fat	diet	(HFD)	
(n	=	4–6).	(b)	F4/80	staining	was	performed	in	20	m	mice	fed	a	CD	and	a	HFD	for	evaluating	inflammation.	(c)	ALT	and	AST	serum	levels	
were evaluated in 20 m mice fed a HFD (n	=	4–5).	(d)	Immunoblot	analysis	of	GRP78,	total	and	phosphorylated	eIF2a,	γH2Ax,	and	p21	
protein levels from liver extract were assessed using transferrin as loading control (n	=	4–5)	in	20	m	HFD‐fed	WT	and	OPN‐KO	mice.	Values	
are means ± SEM. Significant differences are denoted by *p < 0.05, **p < 0.01, and ***p	<	0.001	when	comparing	WT	and	OPN‐KO	mice	
(Student's t test)
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in vivo results are supported by in vitro findings. In addition, liver 
OPN is p53 regulated, and it plays a role in ensuring OPN secretion 
in response to senescence. The overall data suggest that OPN is a 
protective factor that counteracts senescence.
4  | E XPERIMENTAL PROCEDURES
4.1 | Human samples
This	 study	 included	 123	 patients;	 42	 were	 nonobese	 and	 81	 were	
obese. Individuals were considered nonobese when presenting a BMI 
lower than 30 kg/m2 and obese when the BMI was higher than 30 kg/




individuals with normal liver (NL). The nonobese group was comprised 
of	 13	 individuals	 with	 NAFLD	 and	 29	 control	 individuals	 with	 NL.	
Steatosis was assessed as outlined by Kleiner et al. (2005). The study 
was performed in agreement with the Declaration of Helsinki and with 
local and national laws. The Human Ethics Committee of the University 
Hospital Santa Cristina and the Ethical committee of clinical research of 
the	Basque	Country	approved	the	study	procedures.	Written	informed	
consent was obtained from all patients before inclusion in the study.
4.2 | Animals
3‐,	10‐,	and	20‐month‐old	WT	and	OPN‐KO	female	mice	were	used.	





the role of p53 in OPN regulation. For assessing OPN expression in 
p53-KO animals, mice were maintained on a rodent CD (Teklad Global 
18%	Protein	Rodent	Diet	2018S;	Harlan	Laboratories	INC.,	USA)	or	a	
rodent	HFD	(Bioserv	S3282,	60%	Fat)	and	water	ad	libitum	for	4	weeks.	




were	approved	by	 the	Ethics	Committee	 for	Animal	Welfare	of	 the	
University of the Basque Country UPV/EHU and were conducted in 
conformity with the EU Directives for animal experimentation.
4.3 | In vivo adenoviral gene transfer
Wild‐type	 (WT)	mice	 and	 p53‐KO	mice	were	 injected	 by	 tail	 vein	




4.4 | Glucose and insulin tolerance tests
For	glucose	tolerance	test	(GTT),	mice	were	fasted	for	4	hr	and	then	
were administered a glucose solution (2 g/kg body weight) by oral 
gavage. Blood glucose levels were measured before glucose admin-
istration	(time	0)	and	15,	30,	60,	and	120	min	postgavage	using	blood	
strips. For insulin sensitivity test (ITT), mice were injected intraperi-
toneally 1 U insulin/kg body weight and glucose levels were meas-
ured as described above for glucose tolerance test.
4.5 | Glucose and insulin measurement
Glucose blood levels were measured using blood strips. For insu-
lin	measurement,	an	ultrasensitive	mouse	Insulin	ELISA	kit	(catalog	




Culture	 Collection	 (ATCC).	 Cells	 were	 maintained	 in	 Dulbecco's	
modified Eagle's medium supplemented with fetal bovine serum 
10% (v/v), penicillin-streptomycin 1%, glutamine, and amphotericin 
B 1%. Cells were kept at 37°C within a 95% humidified atmosphere 
containing 5% carbon dioxide in an incubator. Depending on the ex-
periment,	cells	were	plated	in	60‐mm	culture	dishes,	6‐well	plates,	or	
in	24‐well	culture	plates.
F I G U R E  7   Liver OPN is p53 regulated. (a) Protein levels of p53 were evaluated by immunohistochemistry in liver sections of 3-, 10-, and 
20‐month‐old	(m)	wild‐type	(WT)	mice	(n	=	3–5).	(b)	OPN	protein	levels	from	liver	homogenates	were	measured	in	WT	and	p53‐KO	male	and	
female	mice	fed	a	chow	diet	(CD)	and	a	high‐fat	diet	(HFD)	by	immunoblotting	using	glyceraldehyde‐3‐phosphate	dehydrogenase	(GAPDH)	





(Palbo)	were	measured	by	ELISA	(n	=	4–8).	Values	are	means	±	SEM. Significant differences are denoted by *p < 0.05, **p < 0.01, and 
***p < 0.001 (Student's t test)
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4.7 | Cell transfection
For	 knocking‐down	 experiments,	 a	 commercial	 siRNA	 was	 used	
against	 osteopontin	 (SPP1	 gene)	 and	 p53	 (TP53	 gene)	 (Ambion	
CA,	USA).	Negative	controls	were	 included	 in	each	assay	by	using	
Silencer™	 Select	 Negative	 Control	 siRNA	 (Ambion	 CA,	 USA).	
Reverse	transfection	was	performed	using	RNAiMAX	lipofectamine	
(Invitrogen	 Life	 Technologies,	 USA)	 in	 Opti‐MEM	 media.	 Briefly,	
Lipofectamine	and	siRNA	were	diluted	separately	in	Opti‐MEM	and	
then	dilutions	were	mixed	and	incubated	for	20	min	at	RT.	24	hr	after	




Senescence inductor Palbociclib 2 μM was dissolved in DMSO and 
filtered.	24	hr	after	transfection,	HepG2	cells	were	exposed	to	pal-
bociclib or vehicle, which was added to the regular complete media. 
Cells	 were	 collected	 4	 days	 after	 palbociclib	 treatment	 for	 their	
study.
4.9 | Hydrogen peroxide treatment
Hydrogen peroxide (H2O2) was used for senescence induction. 
24	hr	after	plating,	cells	were	exposed	to	H2O2 700 μM or vehicle 
for 1 hr. Then, treatment media was replaced and fresh media was 
added.	Cells	were	collected	4	days	after	H2O2 treatment for their 
study.





For	 the	 immunoblots,	 samples	 were	 separated	 to	 SDS‐PAGE	 and	
proteins	 were	 transferred	 to	 nitrocellulose	 membranes.	 Western	
blotting was performed using the primary antibody of interest.
4.12 | [3H]Acetate and [3H]oleate incorporation
For de novo lipogenesis analysis, primary hepatocytes (1.5 × 106 cells/
plate)	or	liver	slices	(40	mg)	were	incubated	with	sodium	[3H]acetate 
(84	mCi/	mmol;20	µCi/mL;	20	µM).	For	esterification	analysis	pri-
mary hepatocytes (1.5 × 106	 cells/plate)	were	 incubated	with	 [3H]
oleate	(54	mCi/mmol;	2	µCi/mL;	20	µM)	and	liver	slices	(40	mg)	were	
incubated	with	 [3H]oleate	 (54	mCi/mmol;	 2	 µCi/mL;	 800	 µM).	 At	
240	min,	cells	and	mediums	were	collected.	To	quantify	the	radioac-
tivity	incorporated	from	[3H]acetate	and	[3H]oleate into lipids, lipids 
were	extracted	and	separated.	After	the	scraping	of	the	correspond-
ing bands into a vial containing scintillation, liquid radioactivity was 
determined.
4.13 | Fatty acid oxidation measurement
Beta oxidation was assessed as described before and detailed in 
Appendix	S1.
4.14 | Osteopontin ELISA
For quantification of serum and cell supernatant OPN concentration, 
a	Human	or	Mouse	OPN	Quantikine	ELISA	kit	 (R&D	Systems)	was	
used following manufacturer's instructions.
4.15 | Histochemistry




Protein concentration was measured using commercially 
Bicinchoninic	Acid	Reagent(Thermo	Fisher	Scientific	Inc).
4.17 | Statistical analysis
Data are represented as mean ± SEM. Differences between groups 
were tested using Student's t	 test,	 two‐way	ANOVA.	 Significance	
was defined as p < 0.05. Correlation analysis was tested using the 
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